[go: up one dir, main page]

AR070555A1 - Estructura cristalina del dominio cc2-lz de nemo - Google Patents

Estructura cristalina del dominio cc2-lz de nemo

Info

Publication number
AR070555A1
AR070555A1 ARP090100356A ARP090100356A AR070555A1 AR 070555 A1 AR070555 A1 AR 070555A1 AR P090100356 A ARP090100356 A AR P090100356A AR P090100356 A ARP090100356 A AR P090100356A AR 070555 A1 AR070555 A1 AR 070555A1
Authority
AR
Argentina
Prior art keywords
domain
nemo
crystal structure
crystal
conceive
Prior art date
Application number
ARP090100356A
Other languages
English (en)
Inventor
Olivera Grubisha
Fabrice Agou
Elisabeth Fontan
Monika Dorota Kaminska
Michel Veron
Florence Cordier
Jeanne Chiaravalli
Stephane Duquerroy
Original Assignee
Pasteur Institut
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Servier Lab filed Critical Pasteur Institut
Publication of AR070555A1 publication Critical patent/AR070555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Cristal del dominio CC2-LZ de la proteína NEMO de mamífero cuya estructura tridimensional se determino por difraccion de rayos X a una resolucion de aproximadamente 3,25 L. La presente solicitud se refiere igualmente a los métodos de cristalizacion del dominio CC2-LZ. Los cristales de CC2-LZ así como la informacion, obtenidos de sus estructuras cristalinas se utilizan pare identificar y concebir compuestos que interaccionan con CC2-LZ.
ARP090100356A 2008-02-05 2009-02-04 Estructura cristalina del dominio cc2-lz de nemo AR070555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0800605A FR2927080A1 (fr) 2008-02-05 2008-02-05 Structure cristalline du domaine cc2-lz de nemo

Publications (1)

Publication Number Publication Date
AR070555A1 true AR070555A1 (es) 2010-04-21

Family

ID=39638688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100356A AR070555A1 (es) 2008-02-05 2009-02-04 Estructura cristalina del dominio cc2-lz de nemo

Country Status (9)

Country Link
US (1) US8440790B2 (es)
EP (1) EP2240513A2 (es)
JP (1) JP5529759B2 (es)
AR (1) AR070555A1 (es)
AU (1) AU2009227090B2 (es)
CA (1) CA2713884A1 (es)
EA (1) EA020189B1 (es)
FR (1) FR2927080A1 (es)
WO (1) WO2009115664A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20040101907A1 (en) * 2000-09-19 2004-05-27 Bussiere Dirksen E. Characterization of the gsk-3beta protein and methods of use thereof
EP1599497B1 (en) * 2003-02-27 2010-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Crystal structure of the ternary complex of 14-3-3, fusicoccin, and plasma membrane atpase and methods for designing new herbicides
JP5027508B2 (ja) * 2003-09-24 2012-09-19 インスティティ・パスツール ＮＥＭＯオリゴマー化を妨害するように設計されたペプチドによるＮＦ−κＢ活性化の選択的阻害

Also Published As

Publication number Publication date
WO2009115664A2 (fr) 2009-09-24
FR2927080A1 (fr) 2009-08-07
US20110159598A1 (en) 2011-06-30
WO2009115664A3 (fr) 2009-11-26
EA201001228A1 (ru) 2011-04-29
AU2009227090B2 (en) 2012-05-03
EP2240513A2 (fr) 2010-10-20
EA020189B1 (ru) 2014-09-30
US8440790B2 (en) 2013-05-14
CA2713884A1 (fr) 2009-09-24
JP5529759B2 (ja) 2014-06-25
AU2009227090A1 (en) 2009-09-24
JP2011516405A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
CR20120031A (es) Derivados de 5-fluoropirimidinona
CY1122543T1 (el) Δεσμευοντα μορια για bcma και cd3
GT201200181A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas
UY30662A1 (es) Método de cristalizacion discontinuo para cristalizar un anticuerpo anti-htnfalfa, cristales de anticuerpo obtenido por dicho método, composiciones que los conitenen y aplicaciones
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
ME02694B (me) Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu
BR112012025872B8 (pt) primidinas modificadas na posição-5
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
DOP2009000190A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides
MX375064B (es) Proceso sintetico libre de plantilla organiga para la produccion de un material zeolítico de la estructura tipo cha.
BR112013030830A2 (pt) processo de preparação de composto da fórmula (i) e estetrol obtido diretamente por meio do processo
AR071997A1 (es) Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
MX360062B (es) Metodos de elaboracion de fenilacetato de l-ornitina.
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
MA32215B1 (fr) Cristal de compose de benzimidazole
EA201591530A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
MX2018016329A (es) Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
AR102915A1 (es) Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
MX388969B (es) Formulas cristalinas de grapiprant.
PE20081556A1 (es) Formas cristalinas de glyt1
MX2015009390A (es) Metodo de produccion de composiciones de beta-caseina y productos relacionados.
AR085915A1 (es) Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas
BR112014027994A2 (pt) métodos de cristalização para purificação de anticorpos monoclonais
NZ596326A (en) Novel solvate crystals

Legal Events

Date Code Title Description
FA Abandonment or withdrawal